Conference call and webcast presentationWe will host a conference call and webcast presentation on 2 August 2024, at 14:00 CET / 8:00 am ET. To participate...
Mechelen, België; 14 juni 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat het bemoedigende nieuwe resultaten zal presenteren van de...
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing...
Our scientific presence at EHA 2024 New preliminary Phase 1/2 data for ATALANTA-1 in R/R NHL SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T CELLS (GLPG5101) IN...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’...
Adaptimmune en Galapagos zullen een klinische proof-of-concept studie uitvoeren om de veiligheid en werkzaamheid te evalueren van uza-cel (nieuwe generatie MAGE-A4 TCR T-celtherapie) geproduceerd op...